Iradimed Corporation will release its second-quarter fiscal 2026 results before the market opens on July 31, 2026. In the first quarter of fiscal 2026, net revenue rose 12.7% to $21.98 million, driven by growth in MRI-compatible IV infusion pump systems and patient vital signs monitoring systems. Total devices revenue increased to $15.39 million from $12.96 million a year earlier, with IV infusion pump systems revenue reaching $7.66 million and patient vital signs monitoring systems revenue at $7.11 million. Net income attributable to Iradimed grew to $5.82 million, or $0.45 per diluted share, compared with $4.69 million, or $0.37 per share, in the prior-year quarter. For the second quarter, the company expects revenue of $20.0 million to $21.0 million and diluted earnings per share of $0.40 to $0.44, while reaffirming full-year 2026 revenue guidance of $91.0 million to $96.0 million.
Iradimed CoStrong Q1 results and raised guidance for Q2 and full year 2026 indicate positive financial performance.